Freeline Therapeutics Holdings Stock Fundamentals
| FRLNDelisted Stock | USD 4.31 0.28 6.10% |
Freeline Therapeutics Holdings fundamentals help investors to digest information that contributes to Freeline Therapeutics' financial success or failures. It also enables traders to predict the movement of Freeline Stock. The fundamental analysis module provides a way to measure Freeline Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Freeline Therapeutics stock.
Freeline |
Freeline Therapeutics Holdings Company Current Valuation Analysis
Freeline Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Freeline Therapeutics Current Valuation | 2.78 M |
Most of Freeline Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Freeline Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Freeline Therapeutics Holdings has a Current Valuation of 2.78 M. This is 99.98% lower than that of the Biotechnology sector and 99.94% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.98% higher than that of the company.
Freeline Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Freeline Therapeutics's current stock value. Our valuation model uses many indicators to compare Freeline Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Freeline Therapeutics competition to find correlations between indicators driving Freeline Therapeutics's intrinsic value. More Info.Freeline Therapeutics Holdings is rated # 3 in return on equity category among its peers. It is rated # 4 in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Freeline Therapeutics' earnings, one of the primary drivers of an investment's value.Freeline Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Freeline Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Freeline Therapeutics could also be used in its relative valuation, which is a method of valuing Freeline Therapeutics by comparing valuation metrics of similar companies.Freeline Therapeutics is currently under evaluation in current valuation category among its peers.
Freeline Fundamentals
| Return On Equity | -1.01 | |||
| Return On Asset | -0.56 | |||
| Current Valuation | 2.78 M | |||
| Shares Outstanding | 4.36 M | |||
| Shares Owned By Insiders | 1.09 % | |||
| Shares Owned By Institutions | 45.88 % | |||
| Number Of Shares Shorted | 23.93 K | |||
| Price To Book | 0.94 X | |||
| Price To Sales | 45.40 X | |||
| Revenue | 622 K | |||
| EBITDA | (64.84 M) | |||
| Net Income | (49.93 M) | |||
| Cash And Equivalents | 90 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 5.92 M | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 3.68 X | |||
| Book Value Per Share | 6.89 X | |||
| Cash Flow From Operations | (64.24 M) | |||
| Short Ratio | 1.92 X | |||
| Earnings Per Share | (11.40) X | |||
| Target Price | 8.25 | |||
| Number Of Employees | 152 | |||
| Beta | 0.66 | |||
| Market Capitalization | 28.24 M | |||
| Total Asset | 86.64 M | |||
| Retained Earnings | (445.35 M) | |||
| Working Capital | 36.66 M | |||
| Z Score | -6.29 | |||
| Net Asset | 86.64 M |
About Freeline Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Freeline Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Freeline Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Freeline Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. Freeline Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 235 people.
Pair Trading with Freeline Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Freeline Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Freeline Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Freeline Stock
| 0.7 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.64 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.56 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.35 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.34 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
The ability to find closely correlated positions to Freeline Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Freeline Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Freeline Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Freeline Therapeutics Holdings to buy it.
The correlation of Freeline Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Freeline Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Freeline Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Freeline Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Freeline Stock
If you are still planning to invest in Freeline Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Freeline Therapeutics' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |